RecruitingNCT06065852
Renal
Bartter Syndrome
Also known as hypokalemic alkalosis with hypercalciuria, renal tubular hypokalemia, salt-wasting nephropathy
Bartter syndrome encompasses a group of autosomal recessive renal tubular disorders caused by mutations in genes encoding ion transporters in the thick ascending limb of the loop of Henle, resulting in salt wasting, hypokalaemic metabolic a
ORPHA:112 ↗Gene SLC12A1Gene KCNJ1Gene CLCNKB (multiple)Prevalence Approximately 1 in 1,000,000Onset Antenatal / Neonatal (Types I–III); childhood (Type IV–V)
1
studies recruiting now
as of 7 Sept 2026
5
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
4 Oct 2023
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Bartter Syndrome studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Bartter Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: European Rare Kidney Disease Reference Network (ERKNet) Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Bartter Syndrome
Bartter syndrome encompasses a group of autosomal recessive renal tubular disorders caused by mutations in genes encoding ion transporters in the thick ascending limb of the loop of Henle, resulting in salt wasting, hypokalaemic metabolic alkalosis, and secondary hyperaldosteronism. The neonatal forms (Types I and II) present with life-threatening polyuria, dehydration, and electrolyte disturbances in utero or at birth, while Type III (CLCNKB mutation) is more variable in severity. Long-term complications include nephrocalcinosis and progressive renal impairment.
Common clinical features
Polyhydramnios and premature birth (severe neonatal types)Severe neonatal polyuria and dehydrationHypokalaemia and metabolic alkalosisFailure to thrive and growth retardationSalt craving and polydipsiaNephrocalcinosisMuscle weakness and cramps
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Bartter Syndrome. Not eligibility rules; those are set by each study.
- Genotype confirmation specifying Bartter subtype (I–V) is essential as disease severity, age of onset, and eligibility criteria differ substantially between subtypes.
- Electrolyte profiles (potassium, chloride, bicarbonate, aldosterone, renin) at baseline and on current supplementation therapy must be documented; trials may require electrolytes to be within defined ranges at screening.
- Some trials exclude patients on high-dose potassium supplementation or prostaglandin synthetase inhibitors; clarify medication requirements with the coordinating centre.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).